Yulia I. Davydova

Yulia I. Davydova

Auto-generated profile, based on publicly available information

Yulia I. Davydova

National Medical Research Center for Children’s Health

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2021 in L.O. Badalyan Neurological Journal
Verified
Journal Article
Closed access
PDF file
AKAleksey L. Kurenkov
Aleksey L. Kurenkov
LKLyudmila M. Kuzenkova
Lyudmila M. Kuzenkova
LPLale A. Pak
Lale A. Pak
BBBella I. Bursagova
Bella I. Bursagova
TPTatyana V. Podkletnova
Tatyana V. Podkletnova
KSKirill Savostyanov
Kirill Savostyanov
Duchenne muscular dystrophy (DMD) is a disease with an X-linked recessive type of inheritance, belonging to a group of disorders with primary muscle damage, caused by pathogenic variants in the DMD gene and associated with dysfunction of the dystrophin protein. Since DMD is manifested by the gradual development of progressive, mainly proximal muscle weakness, the differential diagnosis is primarily carried out in the group of diseases with muscle damage - myopathies. Among these diseases, the leading candidates for differential diagnosis are hereditary myopathies (limb-girdle muscular dystrophies, facioscapulohumeral dystrophy, congenital muscular dystrophies, glycogenoses - the most common juvenile form of glycogenosis type II (Pompe disease)) and, much less often, congenital myopathies and other conditions of neuromuscular diseases). When conducting a differential diagnosis in a child with suspected DMD, the age of the onset of the disease, early initial clinical manifestations and the development of symptoms as they grow, genealogical analysis, laboratory tests (the level of creatine kinase, aspartate aminotransferase, alanine aminotransferase in blood serum), instrumental (electromyography, magnetic resonance imaging of the brain and muscles) and molecular genetics (polymerase chain reaction, multiplex ligation-dependent probe amplification, next-generation sequencing, Sanger sequencing, etc.) of studies, and in some cases, muscle biopsy data. Knowledge of the nuances of the differential diagnosis allows establishing a genetic diagnosis of DMD as early as possible, which is extremely important for the formation of the prognosis of the disease and the implementation of all available treatment methods, including pathogenetic therapy, and is also necessary for medical and genetic counselling of families with DMD patients.

28 December 2023 in L.O. Badalyan Neurological Journal
Verified
Journal Article
Open access
PDF file
LGLeila Gandaeva
Leila Gandaeva
EBElena N. Basargina
Elena N. Basargina
YDYulia I. Davydova
Yulia I. Davydova
YBYulia Sergeevna Burykina
Yulia Sergeevna Burykina
ИСИрина В. Сильнова
Ирина В. Сильнова
KSKirill Savostyanov
Kirill Savostyanov
Introduction. Acyl-CoA dehydrogenase 9 deficiency (mitochondrial complex I deficiency) is an autosomal recessive disease from the heterogeneous group of disorders of mitochondrial β-oxidation of fatty acids caused by mutations in the ACAD9 gene. The disease is characterized by a wide range of clinical manifestations, the most common of which are metabolic acidosis, hypertrophic cardiomyopathy, muscle hypotonicity, and impaired motor skills. The article presents the first Russian clinical observation of a rare variant of hypertrophic cardiomyopathy with early debut in a patient with mitochondrial complex I deficiency caused by homozygous mutation c.659C>T (p.A220V) in the ACAD9 gene and emphasizes the importance of early diagnosis of the disease and complex drug therapy to prevent the development of severe complications. Objective: to describe the clinical course and management of a patient with the pathogenic c.659C>T (p.A220V) variant of the ACAD9 gene. Detailed analysis of anamnesis data, results of clinical, laboratory, instrumental diagnostic methods, and molecular genetic research performed using high-throughput sequencing and direct Sanger sequencing technology. The article presents a literature review and detailed data on clinical observation of a child with homozygous c.659C>T (p.A220V) mutation in the ACAD9 gene diagnosed on the basis of the cardiology department of the National Medical Research Center for Children’s Health. Early disease markers and possibilities of complex drug therapy to prevent the development of severe complications are described. Conclusion. Disruption of mitochondrial beta-oxidation of fatty acids is a heterogeneous group of inherited diseases due to abnormal mitochondrial beta-oxidation and transport of carnitine and fatty acids in mitochondria. A feature of these diseases is the multisystem nature of the lesion and its progressive course. In some cases, the initial clinical manifestations may be various disorders of the cardiovascular system (cardiomyopathy, heart rhythm disturbances), which may cause death in neonatal period and early childhood. Early molecular genetic research provides accurate diagnosis and, accordingly, timely prescription of complex therapy.

31 January 2026 in L.O. Badalyan Neurological Journal
Verified
Journal Article
Open access
PDF file
NSNataliya Sdvigova
Nataliya Sdvigova
LGLeila Gandaeva
Leila Gandaeva
ОГОксана Валерьевна Глоба
Оксана Валерьевна Глоба
ИСИрина Вячеславовна Сильнова
Ирина Вячеславовна Сильнова
YDYulia I. Davydova
Yulia I. Davydova
KSKirill Savostyanov
Kirill Savostyanov
Introduction. Oxidative phosphorylation deficiency, type 10 is a rare variant of mitochondrial disease characterized by lactate acidosis, damage to the cardiovascular and central nervous systems. Given the variability of phenotype-genotypic correlations, a detailed description of the clinical picture of the disease is important for understanding possible variants of the course of the disease.Materials and methods. During a molecular genetic study of three hundred fourteen pediatric patients with a guiding diagnosis of hypertrophic cardiomyopathy, one patient with a deficiency of oxidative phosphorylation, type 10, was identified.Results. The analysis of the nature of the disease course during the period of dynamic follow-up (over 3 years) was carried out.Conclusion. Deficiency of oxidative phosphorylation, type 10, is a rare cause of the hypertrophic phenotype of cardiomyopathy. Isolated cases of this disease have been described in the literature, which makes the observation significant for a wide range of specialists (pediatricians, neurologists, cardiologists).Compliance with ethical standards. Voluntary informed consent was obtained from the patient’s legal representative for the publication of material related to the patient in Russian and foreign medical periodicals (dated October 1, 2024). Contribution:Shifova N.A. — concept and design of research, collection and processing of material, writing, editing;Gandaeva L.A. — editing;Globa O.V. — editing;Silnova I.V. — editing;Davydova Yu.I. — editing;Basargina E.Y. — editing;Savostyanov K.V. — the concept and design of the study.All co-authors are responsible for the integrity of all parts of the manuscript and approval of its final version.Funding. The study had no sponsorship.Conflict of interest. The authors declare no conflict of interest.Received: August 18, 2025Accepted:September 30, 2025Published: January 31, 2026

24 May 2024 in Neuromuscular Diseases
Verified
Journal Article
Open access
PDF file
OKO. B. Kondakova
O. B. Kondakova
AGA. P. Gudkova
A. P. Gudkova
SDS. V. Demyanov
S. V. Demyanov
YDYu. I. Davydova
Yu. I. Davydova
ALA. A. Lyalina
A. A. Lyalina
KSKirill Savostyanov
Kirill Savostyanov
Zhu–Tokita–Takenouchi–Kim syndrome (ZTTK syndrome) is a rare autosomal dominant nuclear speckleopathy characterized by developmental delay, hypotonia, intellectual disability, facial dysmorphism in association with variable brain malformations, musculoskeletal abnormalities and ocular involvement. Currently, 87 cases of ZTTK syndrome have been described worldwide. The syndrome caused by mutations in the SON gene, located on the long arm of chromosome 21 (21q22.11). Nonsense and frameshift mutations have been described in the SON gene. Missense mutations, partial or whole gene deletions are less common.The aim of the work is to analyze the clinical picture and molecular genetic results of patients with confirmed ZTTK syndrome and compare them with data from foreign literature.We observed the one boy and two girls with ZTTK syndrome aged 13 months to 59 months, averaging about 38 months. DNA diagnostic was performed by next generation sequencing. All patients and all parents were confirmed by Sanger sequening. Three pathogenic variants were identified: c.5753_5756delTTAG (p.Val1918Glufs*87), c.1531del (p.Thr511Glnfs*9) and c.403delG (p.Glu135Asnfs*14). The first one was is most common, the other two are novel variants. Most patients had growth, motor and speech delay, seizures, hypotonia, congenital heart defects, urinary tract abnormalities and brain malformations. Comparative analysis of facial features in patients with ZTTK syndrome showed downslanting palpebral fissures, epicantal folds, broad or depressed nasal bridge, flared nares, smooth philtrum, thin upper lip and low set, rotated ears. The use of next generation sequencing as a first‑line test for research and diagnostic of ZTTK syndrome is advisable due to the pronounced clinical polymorphism.

20 August 2025 in L.O. Badalyan Neurological Journal
Verified
Journal Article
Open access
PDF file
ВКВалентина Каверина
Валентина Каверина
LGLeila Gandaeva
Leila Gandaeva
ЕБЕлена Николаевна Басаргина
Елена Николаевна Басаргина
ЮДЮлия Игоревна Давыдова
Юлия Игоревна Давыдова
APAleksander Pushkov
Aleksander Pushkov
KSKirill Savostyanov
Kirill Savostyanov
Introduction. RASopathy pathologies are a unique group of diseases with a multisystem lesion. In the structure of RASopathy, causal genetic variants of the RAF1 are the most common cause of HCM. Among all registered variants of the RAF1, the variant c.770C>T, p.S257L accounts for approximately 50% of cases. Due to the heterogeneity of clinical manifestations in patients with pathogenic variants of the RAF1 gene, the establishment of clinical and genetic features remains an urgent task. The aim of the study. To establish clinical and molecular genetic characteristics of Russian children with Noonan syndrome caused by variants of the RAF1 gene. Materials and methods. Single-center retrospective and prospective cohort study of a sample of ninety eight RASopathy patients aged from 1 month to 18 years. Results. In 19 of 98 patients with RASopathy, there were detected causal variants in the RAF1 gene, which amounted to 19.0%. All genetic variants detected in the RAF1 gene are localized in the cluster part of the gene in the CR2 domain. The c.770C>T, p.S257L variant was the cause of the disease in 10.22% of cases of all RASopathy diagnosed by us and 52.6% of cases of all children with RAF1 gene variants. All patients with RAF1 gene variants showed characteristic extracardiac signs of Noonan syndrome from the first months of life. Myocardial hypertrophy (MCH) was present in all patients, in the vast majority (89.4%) — with LVOT obstruction. When analyzing the course of remodeling, cases of MCH progression were more often noted (78.9%). In 35.7% of patients, one of the adverse cardiovascular events was recorded. Patients with the c.770C >T, p.S257L variant, compared with patients with other genetic variants, already from the first hospitalization demonstrated a more severe phenotype with pronounced signs of HF (p = 0.104), the highest level of NTproBNP (p = 0.003) and LVOTO (p = 0.040). Conclusion. RAF1 gene variants children demonstrate the classic phenotype of Noonan syndrome with the most severe damage to the cardiovascular system and require a comprehensive and dynamic examination with the involvement of specialists of various profiles.

27 March 2026 in M.Ya. Studenikin Russian Pediatric Journal
Verified
Journal Article
Open access
PDF file
OKOlga B. Kondakova
Olga B. Kondakova
AGAnastasia P. Gudkova
Anastasia P. Gudkova
DGDmitry I. Grebenkin
Dmitry I. Grebenkin
SDSemyon V. Demyanov
Semyon V. Demyanov
JDJulia I. Davydova
Julia I. Davydova
КСК. В. Савостьянов
К. В. Савостьянов
Hyperphosphatasia with mental retardation represents an extremely rare group of autosomal recessive metabolic disorders of glycosylation caused by glycosylphosphatidylinositol biosynthesis defect. Hyperphosphatasia is characterized by psychomotor development delay, seizures, variable congenital malformations, and a typical phenotype. A distinctive feature is a consistently elevated serum alkaline phosphatase level. We present a case of an 8-month-old boy with psychomotor retardation and multiple congenital malformations: Hirschsprung’s disease, bilateral obstructive megaureter with ureteral ectopia, and cryptorchidism. Diffuse muscular hypotonia, brachytelephalangy, and a characteristic facial phenotype were noted on examination. The maximum increase in the level of alkaline phosphatase was 1900 U/l. The differential diagnosis was carried out with microdeletion syndromes and Mowat‒Wilson syndrome. According to the results of whole exome sequencing with segregation analysis of the PIGV gene (NM_017837.4), the previously described pathogenic variant c.1022C>A (p.Ala341Glu) and the previously undescribed variant c.103_110del (p.Asp35Cysfs*32) were identified in the trans-configuration. Hyperphosphatasia with mental retardation, type 1, was diagnosed. The data obtained allows to expand knowledge about the phenotypic spectrum and differential diagnosis of hyperphosphatasia, which helps to verify the diagnosis and prevent birth of affected children. Contribution: Kondakova O.B., Savostyanov K.V., Dyakonova E.Yu. — study concept definition of treatment tactics, manuscript editing; Gudkova A.P., Grebenkin D.I., Demyanov S.V., Davydova Yu.I., Tarzyan A.O., Pushkov A.A. — collection and processing, treatment manuscript writing. All co-authors approved the final version of the article and are responsible for the integrity of all parts of the article. Acknowledgments. The study had no sponsorship. Conflict of interest. The authors declare no conflict of interest. Received: December 10, 2025Accepted: March 20, 2026Published: March 27, 2026